MCID: GNR004
MIFTS: 53

Generalized Anxiety Disorder

Categories: Mental diseases

Aliases & Classifications for Generalized Anxiety Disorder

MalaCards integrated aliases for Generalized Anxiety Disorder:

Name: Generalized Anxiety Disorder 12 76 37 55 15 63 73
Anxiety Generalized 55

Classifications:



External Ids:

Disease Ontology 12 DOID:14320
ICD10 33 F41.1
ICD9CM 35 300.02
NCIt 50 C92622
KEGG 37 H01662
UMLS 73 C0270549

Summaries for Generalized Anxiety Disorder

PubMed Health : 63 About generalized anxiety disorder: Everyone feels frightened or very scared every once in a while. In dangerous situations, for instance on the highway, fear can help to protect you. It puts the body in a state of readiness so that it can react to threats quickly. Worries and anxiety about the future, your job or family might also help to guard against danger. For example, by keeping you from making rash decisions that could lead to difficult situations.But if these sorts of fears become overwhelming, they can be very distressing. Some people end up constantly worrying about practically everything. If fears and anxiety overshadow everything else and don’t go away, the person may have developed generalized anxiety disorder (GAD). People with generalized anxiety disorder usually realize that their fears are exaggerated, but they aren’t able to control them. Although it’s difficult to get out of this state, there are treatments that can help.

MalaCards based summary : Generalized Anxiety Disorder, also known as anxiety generalized, is related to dysthymic disorder and anorexia nervosa. An important gene associated with Generalized Anxiety Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Circadian rythm related genes and cAMP signaling pathway. The drugs Alprazolam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and heart, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by long-lasting anxiety that is not focused on any one object or situation.

Wikipedia : 76 Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable and... more...

Related Diseases for Generalized Anxiety Disorder

Diseases related to Generalized Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Related Disease Score Top Affiliating Genes
1 dysthymic disorder 30.4 HTR2A MAOA SLC6A4
2 anorexia nervosa 30.1 BDNF HTR2A SLC6A4
3 alexithymia 29.9 DRD2 HTR1A SLC6A4
4 chronic fatigue syndrome 29.8 HTR1A MAOA SLC6A4
5 antisocial personality disorder 29.8 DRD2 MAOA SLC6A4
6 eating disorder 29.6 BDNF DRD2 SLC6A4
7 neuroleptic malignant syndrome 29.5 DRD2 HTR1A
8 substance abuse 29.3 BDNF DRD2 MAOA SLC6A4
9 social phobia 29.2 DRD2 HTR1A HTR3A MAOA SLC6A4
10 oppositional defiant disorder 29.2 DRD2 MAOA SLC6A2 SLC6A4
11 substance dependence 29.1 BDNF DRD2 MAOA SLC6A4
12 post-traumatic stress disorder 28.9 BDNF DRD2 HTR2A MAOA SLC6A4
13 agoraphobia 28.8 HTR1A MAOA RGS2 SLC6A2 SLC6A4
14 irritable bowel syndrome 28.8 CRHR1 HTR3A SLC6A4 TPH1
15 borderline personality disorder 28.1 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
16 anxiety 28.0 BDNF CRHR1 HTR1A HTR2A HTR3A MAOA
17 depression 27.7 BDNF CRHR1 HTR1A HTR2A HTR3A MAOA
18 personality disorder 27.7 BDNF DRD2 HTR1A HTR2A MAOA SLC6A4
19 obsessive-compulsive disorder 27.3 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
20 attention deficit-hyperactivity disorder 27.1 BDNF DRD2 HTR1A HTR2A MAOA SLC6A2
21 bipolar disorder 26.7 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
22 mood disorder 25.8 BDNF CRHR1 DRD2 HTR1A HTR2A MAOA
23 schizophrenia 25.6 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
24 major depressive disorder 25.3 BDNF CRHR1 DRD2 HTR1A HTR2A HTR3A
25 panic disorder 24.8 BDNF CRHR1 HTR1A HTR2A HTR3A MAOA
26 alcohol dependence 24.7 BDNF CRHR1 DRD2 HTR1A HTR2A HTR3A
27 alzheimer disease 5 10.7 HTR2A SLC6A4
28 schizoid personality disorder 10.6 HTR1A HTR2A
29 hypoactive sexual desire disorder 10.6 HTR1A HTR2A
30 substance-induced psychosis 10.6 HTR1A HTR2A
31 atypical depressive disorder 10.5 MAOA SLC6A4
32 schizophrenia 5 10.4 HTR2A HTR3A
33 psychosexual disorder 10.4 HTR1A HTR2A SLC6A4
34 specific developmental disorder 10.4 BDNF SLC6A2 SLC6A4
35 rumination disorder 10.3 HTR1A HTR3A
36 kleptomania 10.3 HTR1A MAOA SLC6A4
37 alcohol-induced mental disorder 10.3 DRD2 SLC6A4
38 endogenous depression 10.3 BDNF MAOA SLC6A4
39 tardive dyskinesia 10.2 DRD2 HTR2A
40 motion sickness 10.2 HTR1A HTR3A
41 premature ejaculation 10.2 HTR1A HTR3A SLC6A4
42 aging 10.2
43 alcoholic psychosis 10.2 DRD2 HTR2A SLC6A4
44 bruxism 10.2 DRD2 HTR2A SLC6A4
45 torticollis 10.2 DRD2 TSPO
46 temporal lobe epilepsy 10.2 BDNF HTR1A TSPO
47 dyspepsia 10.2 HTR1A HTR3A SLC6A4
48 autism spectrum disorder 10.1 BDNF HTR2A SLC6A4
49 intermittent explosive disorder 10.1 HTR1A SLC6A4
50 bipolar i disorder 10.1 BDNF HTR1A HTR2A SLC6A4

Comorbidity relations with Generalized Anxiety Disorder via Phenotypic Disease Network (PDN): (show all 19)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Dependent Personality Disorder Dysthymic Disorder
Esophagitis Histrionic Personality Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Irritable Bowel Syndrome
Major Depressive Disorder Obsessive-Compulsive Disorder
Obsessive-Compulsive Personality Disorder Osteoporosis
Personality Disorder Schizophreniform Disorder
Somatization Disorder

Graphical network of the top 20 diseases related to Generalized Anxiety Disorder:



Diseases related to Generalized Anxiety Disorder

Symptoms & Phenotypes for Generalized Anxiety Disorder

GenomeRNAi Phenotypes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR3A SLC6A4 HTR1A

MGI Mouse Phenotypes related to Generalized Anxiety Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 MAOA CRHR1 RGS2 SLC6A2 DRD2 SLC6A4
2 cardiovascular system MP:0005385 10.02 MAOA CRHR1 RGS2 SLC6A2 DRD2 SLC6A4
3 homeostasis/metabolism MP:0005376 9.96 BDNF MAOA CRHR1 SLC6A2 DRD2 SLC6A4
4 endocrine/exocrine gland MP:0005379 9.87 BDNF CRHR1 DRD2 SLC6A4 HTR2A HTR3A
5 integument MP:0010771 9.63 HTR3A BDNF SLC6A2 DRD2 SLC6A4 TPH1
6 muscle MP:0005369 9.43 RGS2 DRD2 SLC6A4 HTR2A TPH1 HTR3A
7 nervous system MP:0003631 9.28 BDNF MAOA RGS2 CRHR1 SLC6A2 DRD2

Drugs & Therapeutics for Generalized Anxiety Disorder

PubMedHealth treatment related to Generalized Anxiety Disorder: 63

There are different ways to gradually get a handle on an anxiety disorder. It is unrealistic to expect a quick and simple “cure,” but you can find better ways to deal with stress and anxiety. Medication may also relieve some of the symptoms. There are different kinds of treatment approaches:Psychological treatments: These include approaches like cognitive behavioral therapy. This therapy can help you to learn how to control and then change your thoughts and fears.Relaxation techniques such as autogenic training and progressive muscle relaxation can help you to relax and handle stress better. These techniques are often part of psychological treatment.Medication: The most commonly used medications for anxiety disorders are antidepressants. Some people also use herbal sedatives such as valerian.Self-help: Self-help groups offer you the opportunity to share your thoughts, feelings and experiences with others who have the same condition. Some people also find it helpful to learn more about the disorder – be it from books, information leaflets or on the Internet.It is hard to get a handle on severe anxiety, but many people succeed over time. A therapist can help to reveal the underlying patterns of the worries and anxiety. With their guidance, it is possible to learn how to control harmful thoughts and behavior patterns so that they no longer dominate your life. It can take a lot of patience to find your way back to a life with less anxiety, but a noticeable improvement can often already be achieved after a few weeks.

Drugs for Generalized Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 437)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 28981-97-7 2118
2
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
3
Glatiramer Acetate Approved, Investigational Phase 4,Phase 2,Phase 3 147245-92-9 3081884
4
Interferon beta-1b Approved Phase 4,Phase 2,Phase 3 145155-23-3
5
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Sertraline Approved Phase 4,Phase 2,Phase 3,Not Applicable 79617-96-2 68617
8
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
9
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
10
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
11
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
12
Nicotine Approved Phase 4,Phase 2,Not Applicable 54-11-5 942 89594
13
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821
14
Tramadol Approved, Investigational Phase 4,Phase 2,Not Applicable 27203-92-5 33741
15
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable 2216-51-5 16666
16
Buspirone Approved, Investigational Phase 4,Phase 2,Not Applicable 36505-84-7 2477
17
Lorazepam Approved Phase 4,Phase 2,Not Applicable 846-49-1 3958
18
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
19
Eszopiclone Approved, Investigational Phase 4,Phase 2 138729-47-2 969472
20
Ziprasidone Approved Phase 4 146939-27-7 60854
21
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 61869-08-7 43815
22
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
23
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
24
Tiagabine Approved, Investigational Phase 4,Phase 3 115103-54-3 60648
25
Zolpidem Approved Phase 4,Not Applicable 82626-48-0 5732
26
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
27
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
28
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
29
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
30
Meperidine Approved Phase 4 57-42-1 4058
31
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
32
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
33
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 1 56-12-2 119
34
Tamoxifen Approved Phase 4,Phase 2 10540-29-1 2733526
35
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
36
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
37
Morphine Approved, Investigational Phase 4 57-27-2 5288826
38
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
39
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
40
Chlordiazepoxide Approved, Illicit, Investigational Phase 4 58-25-3 2712
41
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
42
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
43
Methadone Approved Phase 4 76-99-3 4095
44 Kava Approved, Investigational, Nutraceutical Phase 4,Phase 2 9000-38-8
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
46 Tandospirone Investigational Phase 4 87760-53-0
47 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 GABA Modulators Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1072)
# Name Status NCT ID Phase Drugs
1 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly Completed NCT00701675 Phase 4 sertraline 50 mg daily;sertraline 100 mg daily;Placebo 50 or 100 mg
6 Escitalopram in Patients With Generalized Anxiety Disorder Completed NCT00902564 Phase 4 Escitalopram
7 A Study of Duloxetine in Elderly Generalized Anxiety Disorder Completed NCT01118780 Phase 4 Duloxetine;Placebo
8 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD) Completed NCT00219349 Phase 4 escitalopram
9 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
10 Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder Completed NCT00624780 Phase 4 Pregabalin;Lorazepam;Pregabalin;Placebo
11 Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder Completed NCT00235508 Phase 4 Eszopiclone (Lunesta)
12 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
13 Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) Completed NCT01172652 Phase 4 Ziprasidone;Placebo
14 Drug Therapy for Generalized Anxiety Disorder Among the Elderly Completed NCT00105586 Phase 4 Escitalopram
15 Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder Completed NCT00113295 Phase 4 Continued Paroxetine CR;Quetiapine;Placebo
16 Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial. Completed NCT02039193 Phase 4
17 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
18 Chamomile Therapy for Generalized Anxiety Completed NCT00645983 Phase 4
19 Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR Completed NCT00183274 Phase 4 Venlafaxine XR;Placebo
20 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects Completed NCT01033851 Phase 4
21 A Study of Risperidone Monotherapy in Bipolar Anxiety Completed NCT00167479 Phase 4 risperidone (Risperdal)
22 Aripiprazole for the Treatment of Refractory Anxiety Completed NCT00438386 Phase 4 Aripiprazole
23 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
24 Lorazepam-Induced Toxicity in the Aged Completed NCT00044642 Phase 4 Lorazepam
25 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Completed NCT01201967 Phase 4
26 Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction Completed NCT00174850 Phase 4 Gaitril
27 Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro) Completed NCT00296790 Phase 4 zolpidem tartrate
28 Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder Completed NCT00892463 Phase 4 Quetiapine (Seroquel) XR
29 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
30 Black Cohosh as Alternative Therapy for Treating Menopause-Related Anxiety Completed NCT00120458 Phase 4
31 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
32 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Completed NCT00802919 Phase 4 Varenicline;Placebo for varenicline
33 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
34 Efficacy of Pethidine, Ketorolac And Xylocaine Gel As Analgesics For Pain Control In Shockwave Lithotripsy Completed NCT03032458 Phase 4 Pethidine;Ketorolac;Xylocaine Gel
35 Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial Completed NCT02263872 Phase 4 Minocycline
36 Genomics Used to Improve DEpression Decisions Completed NCT02109939 Phase 4
37 Duloxetine for Menopausal Depression Completed NCT01117857 Phase 4 Duloxetine
38 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
39 Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women Completed NCT00628771 Phase 4
40 A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Completed NCT02875366 Phase 4 LUM/IVA;Placebo
41 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
42 Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation Completed NCT01164592 Phase 4
43 Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder Recruiting NCT01614041 Phase 4 Usual dose treatment of Tandospirone;Comparative high dose of tandospirone treatment
44 Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities Recruiting NCT01975480 Phase 4 Desvenlafaxine
45 Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial Recruiting NCT02219880 Phase 4
46 Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders Recruiting NCT03277339 Phase 4 Paroxetine
47 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Recruiting NCT02777905 Phase 4
48 Ketamine Infusion for Adolescent Depression and Anxiety Recruiting NCT02579928 Phase 4 Ketamine;Midazolam
49 Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease Recruiting NCT02622022 Phase 4 Morphine hydrochloride
50 Treatments for Anxiety: Meditation and Escitalopram Recruiting NCT03522844 Phase 4 Escitalopram

Search NIH Clinical Center for Generalized Anxiety Disorder

Genetic Tests for Generalized Anxiety Disorder

Anatomical Context for Generalized Anxiety Disorder

MalaCards organs/tissues related to Generalized Anxiety Disorder:

41
Breast, Brain, Heart, Testes, Spinal Cord, Prostate, Lung

Publications for Generalized Anxiety Disorder

Articles related to Generalized Anxiety Disorder:

(show top 50) (show all 826)
# Title Authors Year
1
Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: A cost-effectiveness analysis. ( 29300754 )
2018
2
Efficacy of vortioxetine in working patients with generalized anxiety disorder- ERRATUM. ( 29880074 )
2018
3
Compromised dynamic cerebral autoregulation in patients with generalized anxiety disorder: a study using transfer function analysis. ( 29859053 )
2018
4
Impact of generalized anxiety disorder (GAD) on prehospital delay of acute myocardial infarction patients. Findings from the multicenter MEDEA study. ( 29383439 )
2018
5
Kava for Generalized Anxiety Disorder: A Review of Current Evidence. ( 29641222 )
2018
6
Risk Factors, Clinical Presentations, and Functional Impairments for Generalized Anxiety Disorder in Military Personnel and the General Population in Canada. ( 29304289 )
2018
7
Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. ( 29806492 )
2018
8
A neural biomarker, the error-related negativity, predicts the first onset of generalized anxiety disorder in a large sample of adolescent females. ( 29665048 )
2018
9
Psychiatrists' treatment preferences for generalized anxiety disorder. ( 29266492 )
2018
10
The Diagnostic Value of Malondialdehyde, Superoxide Dismutase and Catalase Activity in Drug NaA^ve, First Episode, Non-Smoker Generalized Anxiety Disorder Patients. ( 29397670 )
2018
11
Working Memory and Motor Activity: A Comparison Across Attention-Deficit/Hyperactivity Disorder, Generalized Anxiety Disorder, and Healthy Control Groups. ( 29704970 )
2018
12
Kundalini Yoga for Generalized Anxiety Disorder: An Exploration of Treatment Efficacy and Possible Mechanisms. ( 29698081 )
2018
13
Intolerance of uncertainty in youth with obsessive-compulsive disorder and generalized anxiety disorder: A transdiagnostic construct with implications for phenomenology and treatment. ( 29426573 )
2018
14
Worry amplifies theory-of-mind reasoning for negatively valenced social stimuli in generalized anxiety disorder. ( 29254067 )
2018
15
Cognitive Behavioral Therapy, Mindfulness, and Hypnosis as Treatment Methods for Generalized Anxiety Disorder. ( 29771217 )
2018
16
How to customize a bona fide psychotherapy for generalized anxiety disorder? A two-arms, patient blinded, ABAB crossed-therapist randomized clinical implementation trial design [IMPLEMENT 2.0]. ( 29614982 )
2018
17
The effect of mindfulness meditation training on biological acute stress responses in generalized anxiety disorder. ( 28131433 )
2018
18
Generalized anxiety disorder and associated factors in adults in the Amazon, Brazil: A population-based study. ( 29747135 )
2018
19
Generalized Anxiety Disorder (GAD) and Comorbid Major Depression with GAD Are Characterized by Enhanced Nitro-oxidative Stress, Increased Lipid Peroxidation, and Lowered Lipid-Associated Antioxidant Defenses. ( 29736827 )
2018
20
Letter to the editor regarding "Generalized anxiety disorder in urban China: Prevalence, awareness, and disease Burden" [J. Affect. Disord. 234 (2018) 89-96]. ( 29945733 )
2018
21
Abnormal spontaneous brain activity in patients with generalized anxiety disorder revealed by resting-state functional MRI. ( 29406370 )
2018
22
A population-based examination of the co-occurrence and functional correlates of chronic pain and generalized anxiety disorder. ( 29703452 )
2018
23
Changing patterns in the prevalence of posttraumatic stress disorder, major depressive episode and generalized anxiety disorder over 24 months following a road traffic crash: Results from the UQ SuPPORT study. ( 29738952 )
2018
24
Client reflections on confirmation and disconfirmation of expectations in cognitive behavioral therapy for generalized anxiety disorder with and without motivational interviewing. ( 29357757 )
2018
25
The efficacy of group metacognitive therapy for children (MCT-c) with generalized anxiety disorder: An open trial. ( 29145078 )
2018
26
Efficacy and Safety of a Formulated Herbal Granula, Jiu Wei Zhen Xin, for Generalized Anxiety Disorder: A Meta-Analysis. ( 29707037 )
2018
27
Neural functional architecture and modulation during decision making under uncertainty in individuals with generalized anxiety disorder. ( 29931835 )
2018
28
An exploratory study of salivary cortisol changes during chamomile extract therapy of moderate to severe generalized anxiety disorder. ( 29080520 )
2018
29
Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder. ( 29721364 )
2018
30
Repetitive transcranial magnetic stimulation of the right parietal cortex for comorbid generalized anxiety disorder and insomnia: A randomized, double-blind, sham-controlled pilot study. ( 29871798 )
2018
31
Difficulty concentrating in generalized anxiety disorder: An evaluation of incremental utility and relationship to worry. ( 29175616 )
2018
32
Prevalence of generalized anxiety disorder and its related factors among infertile patients in Iran: a cross-sectional study. ( 29914527 )
2018
33
Resolution of Anxiety Symptoms in Response to Stimulants in a Patient With Attention-Deficit/Hyperactivity Disorder and Generalized Anxiety Disorder. ( 29917333 )
2018
34
Association Analysis of the Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Gender with Efficacy of Antidepressants in the Chinese Han Population with Generalized Anxiety Disorder. ( 29446659 )
2018
35
The Association between Generalized Anxiety Disorder, Subthreshold Anxiety Symptoms and Fear of Falling among Older Adults: Preliminary Results from a Pilot Study. ( 28452660 )
2017
36
Admixture analysis of age of onset in generalized anxiety disorder. ( 28554154 )
2017
37
Error-Specific Cognitive Control Alterations in Generalized Anxiety Disorder. ( 28871288 )
2017
38
A Preliminary Multimethod Comparison of Sleep Among Adolescents With and Without Generalized Anxiety Disorder. ( 27736237 )
2017
39
Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis. ( 28982121 )
2017
40
Early improvement predicts 8-week treatment outcome in patients with generalized anxiety disorder treated with escitalopram or venlafaxine. ( 29193711 )
2017
41
Association between Internet gaming disorder and generalized anxiety disorder. ( 29280398 )
2017
42
Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. ( 28483071 )
2017
43
Increased methylation of glucocorticoid receptor gene promoter 1<sub>F</sub> in peripheral blood of patients with generalized anxiety disorder. ( 28292649 )
2017
44
Emotion-focused perspective on generalized anxiety disorder: A qualitative analysis of clients' in-session presentations. ( 28893153 )
2017
45
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
46
Biological markers of generalized anxiety disorder. ( 28867939 )
2017
47
Prefrontal and amygdala engagement during emotional reactivity and regulation in generalized anxiety disorder. ( 28501740 )
2017
48
Repetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: A randomized, double-blind sham controlled clinical trial. ( 28533148 )
2017
49
Treatment of Generalized Anxiety Disorder with Gabapentin. ( 29387502 )
2017
50
Aberrant Functional Network Connectivity as a Biomarker of Generalized Anxiety Disorder. ( 29375339 )
2017

Variations for Generalized Anxiety Disorder

Expression for Generalized Anxiety Disorder

Search GEO for disease gene expression data for Generalized Anxiety Disorder.

Pathways for Generalized Anxiety Disorder

Pathways related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
2
Show member pathways
11.94 BDNF DRD2 HTR1A
3 11.71 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
4 11.69 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1
5
Show member pathways
11.61 BDNF DRD2 MAOA
6
Show member pathways
11.56 DRD2 HTR1A HTR2A
7
Show member pathways
11.07 MAOA SLC6A2 SLC6A4
8
Show member pathways
10.85 MAOA SLC6A4
9
Show member pathways
10.75 MAOA TPH1
10 10.55 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1

GO Terms for Generalized Anxiety Disorder

Cellular components related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.56 BDNF DRD2 HTR1A HTR2A
2 integral component of plasma membrane GO:0005887 9.5 CRHR1 DRD2 HTR1A HTR2A HTR3A SLC6A2
3 axon GO:0030424 9.46 BDNF DRD2 HTR2A HTR3A
4 neuron projection GO:0043005 9.02 HTR3A RGS2 SLC6A2 SLC6A4 TPH1

Biological processes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.67 HTR1A HTR2A HTR3A SLC6A2
2 release of sequestered calcium ion into cytosol GO:0051209 9.6 DRD2 HTR2A
3 response to cocaine GO:0042220 9.59 DRD2 HTR3A
4 response to axon injury GO:0048678 9.58 DRD2 TSPO
5 negative regulation of insulin secretion GO:0046676 9.58 DRD2 PSMD9
6 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.57 HTR1A HTR2A
7 behavioral response to cocaine GO:0048148 9.56 DRD2 HTR2A
8 regulation of dopamine secretion GO:0014059 9.55 DRD2 HTR2A
9 temperature homeostasis GO:0001659 9.54 DRD2 HTR2A
10 response to pain GO:0048265 9.52 SLC6A2 TSPO
11 vasoconstriction GO:0042310 9.51 HTR1A SLC6A4
12 memory GO:0007613 9.5 BDNF HTR2A SLC6A4
13 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.49 DRD2 HTR2A
14 negative regulation of voltage-gated calcium channel activity GO:1901386 9.48 CRHR1 DRD2
15 regulation of behavior GO:0050795 9.46 HTR1A HTR2A
16 monoamine transport GO:0015844 9.43 SLC6A2 SLC6A4
17 behavior GO:0007610 9.4 HTR1A HTR2A
18 regulation of hormone secretion GO:0046883 9.26 HTR1A HTR2A
19 dopamine uptake involved in synaptic transmission GO:0051583 9.16 SLC6A2 SLC6A4
20 response to drug GO:0042493 9.02 DRD2 HTR2A SLC6A2 SLC6A4 TSPO
21 serotonin receptor signaling pathway GO:0007210 8.96 HTR1A HTR2A

Molecular functions related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-tubulin binding GO:0048487 9.43 RGS2 SLC6A2
2 neurotransmitter receptor activity GO:0030594 9.4 HTR1A HTR2A
3 G-protein coupled serotonin receptor activity GO:0004993 9.37 HTR1A HTR2A
4 G-protein alpha-subunit binding GO:0001965 9.32 HTR2A RGS2
5 neurotransmitter:sodium symporter activity GO:0005328 9.26 SLC6A2 SLC6A4
6 monoamine transmembrane transporter activity GO:0008504 9.16 SLC6A2 SLC6A4
7 dopamine:sodium symporter activity GO:0005330 8.96 SLC6A2 SLC6A4
8 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR3A

Sources for Generalized Anxiety Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....